Rilexine 600 mg Tablets for Dogs

국가: 영국

언어: 영어

출처: VMD (Veterinary Medicines Directorate)

유효 성분:

Cefalexin

제공처:

Virbac

ATC 코드:

QJ01DB01

INN (International Name):

Cefalexin

약제 형태:

Tablet

처방전 유형:

POM-V - Prescription Only Medicine – Veterinarian

치료 그룹:

Dogs

치료 영역:

Antimicrobial

승인 상태:

Authorized

승인 날짜:

2005-10-24

제품 특성 요약

Revised: May 2022
AN: 01398/2021
Page 1 of 5
SUMMARY OF THE PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Rilexine 600 mg Tablets for dogs
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
One tablet contains:
- Active substance
Cephalexin………………………………………………….600
mg
(as Cefalexin Monohydrate)
For the full list of excipients see section 6.1.
3. PHARMACEUTICAL FORM
Tablets.
Creamy oblong tablet with small brown spots marked with a score line.
The tablets can be divided into halves.
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of bacterial skin infections in dogs (including deep
and superficial
pyodermas) caused by organisms susceptible to cefalexin.
For the treatment of urinary-tract infections in dogs (including
nephritis and cystitis) caused
by organisms susceptible to cefalexin.
4.3 CONTRA-INDICATIONS
Do
not
use
in
animals
which
are
known
to
be
hypersensitive
to
penicillins
and
cephalosporins.
Do not use in rabbits, guinea pigs, hamsters and gerbils.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
As with other antibiotics which are excreted mainly by the kidneys,
unnecessary
accumulation may occur in the body when renal function is impaired. In
case of known
Revised: May 2022
AN: 01398/2021
Page 2 of 5
renal insufficiency, the dose should be reduced and antimicrobials
known to be
nephrotoxic should not be administered concurrently.
This product should not be used to treat puppies of less than 1 kg of
bodyweight.
Use of the product deviating from the instructions given in the SPC
may increase the
prevalence of bacteria resistant to the cefalexin and may decrease the
effectiveness of
treatment with other cephalosporins and penicillins, due to the
potential for cross-
resistance.
Use of the product should be based on susceptibility testing of the
bacteria isolated from
the animal. If this is not possible, therapy